Navigation Links
Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Date:12/10/2010

p://www.amgen.com/">www.amgen.com for full prescribing information.

Denosumab is also marketed as Prolia™ in other indications.

D-CARE: XGEVA Adjuvant Breast Cancer Study Enrolling Patients NowAs part of Amgen's continued commitment to improving outcomes for people living with breast cancer, XGEVA is also being investigated as adjuvant treatment for women with early-stage breast cancer who are at high-risk of disease recurrence. A large Phase 3 study known as D-CARE is comparing the treatment effect of denosumab with that of placebo on prolonging bone metastasis-free survival (BMFS), and on prolonging disease-free survival (DFS). The trial will enroll 4,500 patients. For more information, please visit www.clinicaltrials.gov (identifier number 01077154).

XGEVA FIRST STEP™ COUPON PROGRAMAmgen is committed to supporting patient access to important medicines through innovative programs including our newly established commercial co-pay program for XGEVA, the Safety Net Foundation, which provides free Amgen products to uninsured patients who qualify, and financial support to independent third party co-pay foundations. The XGEVA FIRST STEP™ Coupon Program is a landmark program among oncology commercial co-pay programs, as it is the first program under the medical benefit with no income eligibility requirement.  The program offers a coupon to eligible patients that can be used to help meet their deductible, co-insurance, and/or co-payment requirements under the medical benefit for XGEVA. For more information, please visit http://www.amgenfirststep.com/.

XGEVA Regulatory StatusXGEVA was approved by the FDA for the prevention of SREs in patients with bone metastases from solid tumors on Nov. 18, 2010. XGEVA is not indicated to prevent SREs in patients with multiple myeloma. Administered as a single 120 mg subcutaneo
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Amgen to Present at Deutsche Banks 2010 BioFEST
2. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
3. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
4. Choices
5. Empowerment Competition
6. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
7. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
8. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
9. Amgen Announces Webcast of 2010 Third Quarter Financial Results
10. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
11. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
(Date:10/22/2014)... VIEW, Calif. , Oct. 22, 2014 ... a.m. EDTLOCATION: Online, complimentary registration available at: ... Team Leader Archana Vidyasekar and Visionary Innovation ... computers, WiFi-like wireless electricity, self-assembling materials, nanobots ... ten technologies which will transform our lives ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
(Date:10/22/2014)... 2014 (HealthDay News) -- The United States is ... Ebola-affected nations of West Africa land at one ... infection with the virus. In a statement ... that 94 percent of air passengers from Guinea, ... of these five airports -- New York City,s ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open ... American Institutes for Research (AIR) finds that three out of ... insurance, but 42 percent say they are not likely or ... up for coverage. , The AIR survey found wide gaps ... to calculate correctly how much they owe for a routine ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... July 31 With the world,s,attention focused on ... Miracles -- a 30-minute Sunday morning public affairs ... of real,patients -- will feature two of America,s ... Jenner. Sharing Miracles now shows on 158,television stations ...
... VANCOUVER, July 31 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced ... in Arlington Virginia. This Center is the Company,s first ... markets that CRH has targeted for,expansion. The opening of ... bringing the Company,s total number of Centers to 17., ...
... July 31 The American Association,of PPOs (AAPPO) ... course",for PPO executives on strategies to improve the ... AAPPO Adding Value Initiative will inform AAPPO,members and ... outcomes., (Logo: http://www.newscom.com/cgi-bin/prnh/20060126/CLTH062LOGO ), ...
... Policies Needed, WASHINGTON, July 31 As the ... convening of the,International AIDS Conference in Mexico City, the ... to announce on August 3rd,significantly higher HIV incidence numbers ... infections per year; the new number may be,more than ...
... number of unusual chromosomal changes, particularly structural changes that ... genes. These results were published today in the scientific ... in the structure of the genes in patients with ... number variants. Genetic diseases are caused by a large ...
... an increased risk of developing cardiovascular disease, particularly stroke ... Atherosclerosis , has now led to attempts to ... (hardening of the arteries) is an inflammatory disease in ... and become less elastic. It can cause blood clots ...
Cached Medicine News:Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 2Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 3Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 4Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 5Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 6Health News:CRH Medical Corporation opens center in Virginia 2Health News:AAPPO Launches Short Course Conference Call Series on Value-added Strategies for PPOs 2Health News:Higher Number of HIV Infections Must Translate Into Leadership & Action by U.S. Government 2Health News:Unusual chromosomal changes increase the risk of schizophrenia 2Health News:New discovery may lead to immunization against cardiovascular disease 2
... system, 100-120 V, includes Model 583 gel dryer, ... gel dryer is a vacuum-based gel dryer with ... with variable temperature control and three preprogrammed cycles. ... used for pulling vacuum on gel dryers requiring ...
... The GelAir™ drying system utilizes a hot air ... dryer holds up to four drying frames at ... support for easy viewing. The assembly table is ... for the drying frame. This 230 V, 50 ...
... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
... The Model 583 gel dryer is an ... acrylamide and agarose gels and dries these gels ... The dryer incorporates lid-mounted heater elements which heat ... x 45 cm. This 100-120 V unit includes ...
Medicine Products: